Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A humorous look at the companies that caught our eye, for better or worse, this week

BlackBerry (STAR)

BB - TSX

“BB to the MOON … let’s get this money!!” Scrolling through posts like this on WallStreetBets – the Reddit forum where retail investors conspire to drive up prices of heavily shorted stocks – one gets the sense that the word hubris has never entered these people’s minds. But for now, at least, the Reddit “apes” are winning: Shares of “meme” stocks including BlackBerry, GameStop and AMC Entertainment took off again as short-sellers were forced to cover their positions. AMC is even offering perks including free popcorn to retail investors. It’s the least the company could do after raising more than US$800-million selling shares at ridiculously inflated prices this week.

General Motors (STAR)

GM - NYSE

You know, I was trying to watch some pickup truck ads the other day, but they kept getting interrupted by a hockey game. Anyway, if you’re in the market for a new truck, good news: After cutting vehicle output because of a global semiconductor shortage, General Motors has reallocated some of its chips to boost production of its highly profitable Chevrolet Silverado, GMC Sierra and other pickups. Thanks to this and other moves, the automaker said its first-half earnings will be “significantly better” than it previously forecast. Investors will need a new pickup truck just to carry all the money they’re making on the stock, which has more than doubled in the past year.

Story continues below advertisement

Inter Pipeline (STAR)

IPL - TSX

A year ago, Inter Pipeline was about as popular with investors as ants at a picnic. Slashing your dividend by 72 per cent will do that. But now, as the world is emerging from the pandemic and the energy sector is rebounding, everyone is showering love on the pipeline operator. On Tuesday, Pembina Pipeline announced an all-stock deal to acquire Inter Pipeline for about $8.3-billion or $19.45 a share, only to be topped the next day by Brookfield Infrastructure, which hiked its hostile cash-and-shares offer to about $8.47-billion or $19.75 a share, up from $16.50 previously. Do I hear $20?

Abbott Laboratories (DOG)

ABT - NYSE

The good news for humanity is that COVID-19 cases are falling. The bad news for Abbott Laboratories is that COVID-19 cases are falling. As vaccinations slow the virus’s spread and sales of Abbott’s COVID-19 diagnostic tests decline, the drug maker cut its full-year earnings forecast, sending the stock to a seven-month low. “While it’s positive that these external events and trends signal an accelerated return to normalcy for many countries, they have suddenly and fundamentally impacted market demand for COVID-19 testing,” the company said. Let’s hope demand keeps falling. No offence, Abbott.

Saputo (DOG)

SAP - TSX

There once was a stock called Saputo

From the same town as one P.E. Trudeau

After cheese sales tumbled

The stock price did crumble

And investors were in a bad mood-o.

Story continues below advertisement

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies